A recent study, the D-Lay MS trial, found that high-dose vitamin D3 significantly reduced disease activity in early multiple sclerosis (MS). Patients with clinically isolated syndrome (CIS) who took 100,000 IU of vitamin D every two weeks for 24 months had fewer relapses and new brain lesions compared to those on a placebo.
MRI results showed a clear benefit, with fewer new and contrast-enhancing lesions in the vitamin D group. However, there was no significant difference in clinical relapse rates. The supplement was safe and well-tolerated, with no severe side effects. Patients with severe vitamin D deficiency benefited the most.
Experts suggest vitamin D could be a low-cost, low-risk treatment option for early MS, especially for those without access to disease-modifying therapies. This trial provides strong evidence supporting its effectiveness in reducing disease activity.
For more information:
https://www.medscape.com/viewarticle/high-dose-vitamin-d-curbs-disease-activity-early-multiple-2025a100062t
This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service, or treatment.
